Cargando…
Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model
Cystic fibrosis (CF) is a hereditary disease due to mutations in the CFTR gene and causes mortality in humans mainly due to respiratory infections caused by Pseudomonas aeruginosa. In a previous work we used phage therapy, which is a treatment with a mix of phages, to actively counteract acute P. ae...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365511/ https://www.ncbi.nlm.nih.gov/pubmed/30728389 http://dx.doi.org/10.1038/s41598-018-37636-x |
_version_ | 1783393433663045632 |
---|---|
author | Cafora, Marco Deflorian, Gianluca Forti, Francesca Ferrari, Laura Binelli, Giorgio Briani, Federica Ghisotti, Daniela Pistocchi, Anna |
author_facet | Cafora, Marco Deflorian, Gianluca Forti, Francesca Ferrari, Laura Binelli, Giorgio Briani, Federica Ghisotti, Daniela Pistocchi, Anna |
author_sort | Cafora, Marco |
collection | PubMed |
description | Cystic fibrosis (CF) is a hereditary disease due to mutations in the CFTR gene and causes mortality in humans mainly due to respiratory infections caused by Pseudomonas aeruginosa. In a previous work we used phage therapy, which is a treatment with a mix of phages, to actively counteract acute P. aeruginosa infections in mice and Galleria mellonella larvae. In this work we apply phage therapy to the treatment of P. aeruginosa PAO1 infections in a CF zebrafish model. The structure of the CFTR channel is evolutionary conserved between fish and mammals and cftr-loss-of-function zebrafish embryos show a phenotype that recapitulates the human disease, in particular with destruction of the pancreas. We show that phage therapy is able to decrease lethality, bacterial burden, and the pro-inflammatory response caused by PAO1 infection. In addition, phage administration relieves the constitutive inflammatory state of CF embryos. To our knowledge, this is the first time that phage therapy is used to cure P. aeruginosa infections in a CF animal model. We also find that the curative effect against PAO1 infections is improved by combining phages and antibiotic treatments, opening a useful therapeutic approach that could reduce antibiotic doses and time of administration. |
format | Online Article Text |
id | pubmed-6365511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-63655112019-02-08 Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model Cafora, Marco Deflorian, Gianluca Forti, Francesca Ferrari, Laura Binelli, Giorgio Briani, Federica Ghisotti, Daniela Pistocchi, Anna Sci Rep Article Cystic fibrosis (CF) is a hereditary disease due to mutations in the CFTR gene and causes mortality in humans mainly due to respiratory infections caused by Pseudomonas aeruginosa. In a previous work we used phage therapy, which is a treatment with a mix of phages, to actively counteract acute P. aeruginosa infections in mice and Galleria mellonella larvae. In this work we apply phage therapy to the treatment of P. aeruginosa PAO1 infections in a CF zebrafish model. The structure of the CFTR channel is evolutionary conserved between fish and mammals and cftr-loss-of-function zebrafish embryos show a phenotype that recapitulates the human disease, in particular with destruction of the pancreas. We show that phage therapy is able to decrease lethality, bacterial burden, and the pro-inflammatory response caused by PAO1 infection. In addition, phage administration relieves the constitutive inflammatory state of CF embryos. To our knowledge, this is the first time that phage therapy is used to cure P. aeruginosa infections in a CF animal model. We also find that the curative effect against PAO1 infections is improved by combining phages and antibiotic treatments, opening a useful therapeutic approach that could reduce antibiotic doses and time of administration. Nature Publishing Group UK 2019-02-06 /pmc/articles/PMC6365511/ /pubmed/30728389 http://dx.doi.org/10.1038/s41598-018-37636-x Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Cafora, Marco Deflorian, Gianluca Forti, Francesca Ferrari, Laura Binelli, Giorgio Briani, Federica Ghisotti, Daniela Pistocchi, Anna Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model |
title | Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model |
title_full | Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model |
title_fullStr | Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model |
title_full_unstemmed | Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model |
title_short | Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model |
title_sort | phage therapy against pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365511/ https://www.ncbi.nlm.nih.gov/pubmed/30728389 http://dx.doi.org/10.1038/s41598-018-37636-x |
work_keys_str_mv | AT caforamarco phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel AT defloriangianluca phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel AT fortifrancesca phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel AT ferrarilaura phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel AT binelligiorgio phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel AT brianifederica phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel AT ghisottidaniela phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel AT pistocchianna phagetherapyagainstpseudomonasaeruginosainfectionsinacysticfibrosiszebrafishmodel |